May 12 Quick Takes: Biogen-TMS in stroke deal; plus Minerva, Autobahn-Astellas, Emergent, Magenta, Fosun-BioNTech 

Biogen Inc. (NASDAQ:BIIB) is exercising an option to acquire a next-generation thrombolytic agent from TMS Co. Ltd. The move comes after the Japanese company showed TMS-007 reopened blood vessels and improved functional recovery compared with placebo in patients dosed up to 12 hours after stroke onset, with no incidence of symptomatic intracranial hemorrhage (sICH), in a Phase IIa study.

Approved thrombolytic agents have shown sICH rates as high as 6% in patients treated up to 9 hours after stroke onset, and later treatment is associated with greater risk of sICH...